Every 10-Q that Agenus (AGEN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGEN filings page.
Agenus Inc. reported total revenues of $68,254 (amounts in thousands) for the six months ended June 30, 2026, up from $49,757 a year earlier, driven mainly by $57,291 of non-cash royalty revenue and $10,963 of pre-commercial BOT/BAL product revenue from early access programs.
Net income attributable to common stockholders was $38,567 (thousands) versus a prior-period loss of $53,329, largely reflecting a $40,379 (thousands) gain on the Zydus asset sale and significant non-cash items, while core operations still used $67,149 (thousands) of operating cash. Cash and cash equivalents rose to $18,738 (thousands) at June 30, 2026, excluding $7,616 (thousands) in Zydus-related escrow.
After quarter end, Agenus closed an $85.0 million private placement plus up to $255.0 million of potential warrant exercise proceeds, and now expects existing cash and net placement proceeds to fund operations into the third quarter of 2027. However, management states that additional capital will be needed to complete BOT/BAL development and reach profitability, and accounting standards require disclosure that substantial doubt exists about the company’s ability to continue as a going concern.
Agenus Inc. reported a sharp swing to profitability for the quarter ended March 31, 2026, driven by a major manufacturing asset sale and higher royalty revenue, while still facing significant financial risk.
Total revenue rose to $33.7 million, including $29.1 million of non-cash royalty revenue from GlaxoSmithKline vaccines using its QS‑21 adjuvant and $4.6 million of pre-commercial sales of botensilimab/balstilimab through early access programs. A $40.4 million gain on the sale of its Emeryville and Berkeley manufacturing facilities to Zydus contributed to net income of $39.2 million, or $1.03 per basic share.
The Zydus collaboration brought $91.0 million in cash at closing and up to $50.0 million of additional non-cash consideration tied to future manufacturing services, while Agenus retained significant royalty and milestone obligations, including a $263.4 million liability related to prior royalty financings. Cash and cash equivalents increased to $35.0 million from $3.0 million at year-end 2025, and subsequent at-the-market share sales added $11.7 million. Despite this liquidity improvement, the company disclosed substantial doubt about its ability to continue as a going concern without additional capital, citing a $2.1 billion accumulated deficit and the need to fund late-stage development and potential commercialization of botensilimab plus balstilimab.
Agenus Inc. reported Q3 2025 results. Total revenues were $30.2 million, driven mainly by non-cash royalty revenue. The company posted an operating loss of $4.5 million, but recorded a $100.9 million gain from the deconsolidation of MiNK Therapeutics, leading to net income of $63.9 million for the quarter.
On the balance sheet, cash and cash equivalents were $3.5 million as of September 30, 2025. The principal amount of outstanding debt was $35.6 million, and the liability related to the sale of future royalties and milestones was $295.2 million as of September 30, 2025. Shares outstanding were 34,008,349 as of November 7, 2025.
Management disclosed that, despite post-quarter cash actions—including a $10.0 million Zydus promissory note and $4.5 million raised via at-the-market sales—and anticipated $91.0 million from Zydus Lifesciences agreements in Q1 2026, substantial doubt continues to exist about the company’s ability to continue as a going concern for one year after filing. The quarter also reflects the shift to accounting for MiNK under the equity method (fair value option).
Agenus Inc. reported a six-month net loss of $56.4 million and a weighted average basic and diluted loss per share of $2.03. Cash and cash equivalents were $9.5 million at June 30, 2025, and the company had an accumulated deficit of $2.2 billion and total assets of $185.2 million. The balance sheet shows a large recorded liability related to sale of future royalties and milestones, net of $312.2 million, current liabilities of $234.6 million and stockholders’ deficit attributable to Agenus of $354.6 million.
The company received $75.0 million gross proceeds from the Ligand Purchase Agreement (allocated partly to a royalty liability) and recognized $48.4 million of non-cash royalty revenue in the six months. Subsequent to quarter end it sold ~787,000 shares for net proceeds of ~$5.2 million and expects to receive $75.0 million upfront plus a $16.0 million equity investment from the Zydus transaction upon closing in Q3 2025. Management discloses substantial doubt about going concern for one year after filing and notes ongoing litigation and an SEC subpoena.